Exelixis (EXEL) Stock Forecast & Price Target

Compare

3,120 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXEL Analyst Ratings

Moderate Buy

8 Buy

8 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Exelixis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$43.80

▼(-5.83% Downside)

Based on 16 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $43.80 with a high forecast of $51.00 and a low forecast of $30.00. The average price target represents a -5.83% change from the last price of $46.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","52":"$52","34.75":"$34.8","40.5":"$40.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,34.75,40.5,46.25,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,44.012307692307694,44.59461538461539,45.176923076923075,45.75923076923077,46.34153846153846,46.923846153846156,47.50615384615384,48.08846153846154,48.67076923076923,49.253076923076925,49.83538461538461,50.417692307692306,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,43.458461538461535,43.48692307692308,43.51538461538461,43.543846153846154,43.57230769230769,43.60076923076923,43.629230769230766,43.65769230769231,43.68615384615384,43.714615384615385,43.74307692307692,43.77153846153846,{"y":43.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,42.39692307692307,41.363846153846154,40.33076923076923,39.29769230769231,38.26461538461538,37.23153846153846,36.19846153846154,35.16538461538462,34.13230769230769,33.09923076923077,32.066153846153846,31.033076923076923,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$51.00

Average Price Target$43.80

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Etzer Darout

Barclays

$41

Hold

-11.85%

Downside

Reiterated

12/11/25

Exelixis (EXEL) Receives a Hold from Barclays

Akash Tewari

Jefferies

$46

Buy

-1.10%

Downside

Reiterated

12/11/25

Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

12/11/25

Exelixis's Strategic Oncology Expansion and Pipeline Innovations Justify Buy RatingWe are reiterating Outperform rating on Exelixis shares since we are optimistic that zanza, coupled with several pipeline assets, can help Exelixis grow through Cabometyx’s “patent cliff” that is expected to occur in early 2031.

Stephen Willey

Stifel Nicolaus

$43

Hold

-7.55%

Downside

Reiterated

12/11/25

Stifel Nicolaus Remains a Hold on Exelixis (EXEL)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Exelixis (NASDAQ: EXEL) and Natera (NASDAQ: NTRA)

Leonid Timashev

RBC Capital

$45

Hold

-3.25%

Downside

Reiterated

12/10/25

Exelixis (EXEL) Receives a Hold from RBC Capital

Sean Laaman

Morgan Stanley

$45

Buy

-3.25%

Downside

Reiterated

12/05/25

Exelixis's Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet NeedsWe hosted a KOL discussion with a GI oncology specialist to discuss their views on the treatment landscape in metastatic colorectal cancer (mCRC) and zanzalintinib (zanza) ahead of the expected NDA submission.

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Exelixis initiated with a Peer Perform at Wolfe ResearchExelixis initiated with a Peer Perform at Wolfe Research

Ashwani Verma

UBS

$35→$40

Hold

-14.00%

Downside

Reiterated

11/06/25

Exelixis (EXEL) Gets a Hold from UBS

Yaron Werber

TD Cowen

$44→$51

Buy

9.65%

Upside

Reiterated

11/05/25

Exelixis's Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber4:31 AM Exelixis (NASDAQ: EXEL) Buy (1) ESG $51.00 (Prior $44.00) In-Line – Strong NET Launch Continues – New PT $51 (+$7) View Full Report THE TD COWEN INSIGHT Q3 revs of $598M beat our/cons $590M est. Cabo US sales of $543M (+4% q/q) in-line w/cons. Lower end of FY25 total revs guidance raised to $2.30B (+6% y/y), reflecting strength of NET. to highlight Ph1 data for early pipeline; Ph3 nccRCC (now mid '26) is next key catalyst. PT raised to $51 (+$7) driven by strong NET launch, OpEx tightening & add'l $750M in stock buybacks by YE26. In-Line – NET Share – Q3 non-GAAP EPS $0.78 beat our $0.68 and cons $0.69 ests.

Jason Gerberry

Bank of America Securities

―

Hold

―

Reiterated

11/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (NASDAQ: PRCT), Day One Biopharmaceuticals (NASDAQ: DAWN) and Exelixis (NASDAQ: EXEL)

Robert Burns

H.C. Wainwright

$46→$49

Buy

5.35%

Upside

Reiterated

11/05/25

Exelixis price target raised to $49 from $46 at H.C. WainwrightExelixis price target raised to $49 from $46 at H.C. Wainwright

Michael Schmidt

Guggenheim

―

Hold

―

Downgraded

11/03/25

Exelixis downgraded to Neutral from Buy at GuggenheimExelixis downgraded to Neutral from Buy at Guggenheim

Andrew Berens

Leerink Partners

$38→$48

Buy

3.20%

Upside

Upgraded

10/21/25

Exelixis upgraded to Outperform from Market Perform at LeerinkExelixis upgraded to Outperform from Market Perform at Leerink

Derek Archila

Wells Fargo

$36→$30

Hold

-35.50%

Downside

Reiterated

10/21/25

Exelixis price target lowered to $30 from $36 at Wells FargoExelixis price target lowered to $30 from $36 at Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Etzer Darout

Barclays

$41

Hold

-11.85%

Downside

Reiterated

12/11/25

Exelixis (EXEL) Receives a Hold from Barclays

Akash Tewari

Jefferies

$46

Buy

-1.10%

Downside

Reiterated

12/11/25

Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

12/11/25

Stephen Willey

Stifel Nicolaus

$43

Hold

-7.55%

Downside

Reiterated

12/11/25

Stifel Nicolaus Remains a Hold on Exelixis (EXEL)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Exelixis (NASDAQ: EXEL) and Natera (NASDAQ: NTRA)

Leonid Timashev

RBC Capital

$45

Hold

-3.25%

Downside

Reiterated

12/10/25

Exelixis (EXEL) Receives a Hold from RBC Capital

Sean Laaman

Morgan Stanley

$45

Buy

-3.25%

Downside

Reiterated

12/05/25

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Exelixis initiated with a Peer Perform at Wolfe ResearchExelixis initiated with a Peer Perform at Wolfe Research

Ashwani Verma

UBS

$35→$40

Hold

-14.00%

Downside

Reiterated

11/06/25

Exelixis (EXEL) Gets a Hold from UBS

Yaron Werber

TD Cowen

$44→$51

Buy

9.65%

Upside

Reiterated

11/05/25

Jason Gerberry

Bank of America Securities

―

Hold

―

Reiterated

11/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (NASDAQ: PRCT), Day One Biopharmaceuticals (NASDAQ: DAWN) and Exelixis (NASDAQ: EXEL)

Robert Burns

H.C. Wainwright

$46→$49

Buy

5.35%

Upside

Reiterated

11/05/25

Exelixis price target raised to $49 from $46 at H.C. WainwrightExelixis price target raised to $49 from $46 at H.C. Wainwright

Michael Schmidt

Guggenheim

―

Hold

―

Downgraded

11/03/25

Exelixis downgraded to Neutral from Buy at GuggenheimExelixis downgraded to Neutral from Buy at Guggenheim

Andrew Berens

Leerink Partners

$38→$48

Buy

3.20%

Upside

Upgraded

10/21/25

Exelixis upgraded to Outperform from Market Perform at LeerinkExelixis upgraded to Outperform from Market Perform at Leerink

Derek Archila

Wells Fargo

$36→$30

Hold

-35.50%

Downside

Reiterated

10/21/25

Exelixis price target lowered to $30 from $36 at Wells FargoExelixis price target lowered to $30 from $36 at Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

1 Month

xxx

Success Rate

10/15 ratings generated profit

Average Return

+4.94%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.94% per trade.

3 Months

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.64%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.64% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

15/15 ratings generated profit

Average Return

+33.55%

reiterated a buy rating 2 months ago

Copying Robert Burns's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +33.55% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+49.94%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +49.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXEL has received 24 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. EXEL average Analyst price target in the past 3 months is 43.80.

Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.76 with a range of $0.38 to $0.90. The previous quarter’s EPS was $0.78. EXEL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $607.96M with a range of $530.40M to $631.03M. The previous quarter’s sales results were $597.75M. EXEL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?

Based on analyst ratings, Exelixis’s 12-month average price target is 43.80.

What is EXEL’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for EXEL, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXEL a Buy, Sell or Hold?

Exelixis has a consensus rating of Moderate Buy which is based on 8 buy ratings, 8 hold ratings and 0 sell ratings.

What is Exelixis’s price target?

The average price target for Exelixis is 43.80. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $30.00. The average price target represents -5.83% Decrease from the current price of $46.51.

What do analysts say about Exelixis?

Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of EXEL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Exelixis (EXEL) Stock Forecast & Price Target

EXEL Analyst Ratings

EXEL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exelixis

EXEL Analyst Recommendation Trends

EXEL Financial Forecast

EXEL Earnings Forecast

EXEL Sales Forecast

EXEL Stock Forecast FAQ

Detailed List of Analyst Forecasts